FY2025 EPS Estimates for GoodRx Holdings, Inc. (NASDAQ:GDRX) Increased by Analyst

GoodRx Holdings, Inc. (NASDAQ:GDRX) – Investment analysts at Leerink Partnrs upped their FY2025 earnings estimates for GoodRx in a research note issued to investors on Tuesday, October 1st. Leerink Partnrs analyst M. Cherny now forecasts that the company will earn $0.23 per share for the year, up from their previous forecast of $0.22. The consensus estimate for GoodRx’s current full-year earnings is $0.14 per share.

GoodRx (NASDAQ:GDRX) last released its quarterly earnings data on Thursday, August 8th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a negative net margin of 7.57% and a positive return on equity of 3.63%. The company had revenue of $200.60 million during the quarter, compared to analyst estimates of $200.47 million. During the same quarter in the prior year, the company earned $0.02 EPS. The business’s revenue was up 5.7% on a year-over-year basis.

Several other equities analysts also recently issued reports on GDRX. Citigroup decreased their price objective on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. Morgan Stanley increased their target price on shares of GoodRx from $7.00 to $9.50 and gave the stock an “equal weight” rating in a research note on Monday, June 10th. Royal Bank of Canada reiterated an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. Raymond James upgraded shares of GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price for the company in a research note on Friday, August 9th. Finally, UBS Group decreased their target price on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a research note on Friday, August 9th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, GoodRx has a consensus rating of “Moderate Buy” and a consensus target price of $9.36.

GoodRx Stock Performance

NASDAQ GDRX opened at $7.09 on Thursday. The company has a debt-to-equity ratio of 0.96, a current ratio of 7.32 and a quick ratio of 7.32. GoodRx has a 1 year low of $4.14 and a 1 year high of $9.26. The company has a market capitalization of $2.66 billion, a PE ratio of -709.00, a P/E/G ratio of 3.38 and a beta of 1.37. The company has a fifty day moving average of $7.66 and a two-hundred day moving average of $7.57.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the stock. Algert Global LLC increased its holdings in GoodRx by 10.0% in the second quarter. Algert Global LLC now owns 181,251 shares of the company’s stock valued at $1,414,000 after buying an additional 16,456 shares in the last quarter. Millennium Management LLC increased its stake in shares of GoodRx by 36.5% during the 2nd quarter. Millennium Management LLC now owns 4,121,939 shares of the company’s stock worth $32,151,000 after purchasing an additional 1,102,758 shares in the last quarter. Dark Forest Capital Management LP purchased a new position in shares of GoodRx during the 2nd quarter worth approximately $86,000. Deerfield Management Company L.P. Series C purchased a new position in shares of GoodRx during the 2nd quarter worth approximately $173,000. Finally, AQR Capital Management LLC increased its stake in shares of GoodRx by 181.1% during the 2nd quarter. AQR Capital Management LLC now owns 46,159 shares of the company’s stock worth $360,000 after purchasing an additional 29,741 shares in the last quarter. 63.77% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total value of $83,921.22. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 4.17% of the stock is owned by insiders.

About GoodRx

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.